Adagene Inc. is a clinical-stage biopharmaceutical company whose American Depositary Shares trade on the Nasdaq under the ticker ADAG. Four current analyst targets form the basis of the central figure used here: H.C. Wainwright at $7.00 (October 2026), LifeSci Capital at $8.00 (September 2026), Chardan Capital at $9.00 (September 2026, initiation), and Guggenheim at $10.00 (September 2026, after raising its target from $9). The arithmetic mean of these four is $8.50.
These objectives are all Buy ratings, but the $7.00-to-$10.00 spread — and aggregator data that shows a high near $17 — indicates genuine disagreement about the company's value. The reasoning is consistent: analysts see substantial upside if muzastotug, a masked anti-CTLA-4 antibody, succeeds in late-line colorectal cancer, but they assign different probabilities to that binary outcome. Morgan Stanley, by contrast, carries a Hold rating without a published target, a reminder that the view is not unanimous.
Adagene closed near $2.58 in late October 2026, toward the lower portion of a 52-week range of roughly $1.30 to $4.85. Reaching $8.50 would require a gain of about 230%, which is a very large move. The stock trades near its cash value — roughly $128 million in cash against a small enterprise value — meaning the market is assigning little credit to the pipeline ahead of definitive data.
A path toward the target would likely run through successful execution of the randomized Phase 2 study of muzastotug in microsatellite stable colorectal cancer (MSS CRC), a setting where PD-1 therapy alone has historically shown little activity. Encouraging early data — a 31% confirmed objective response rate (ORR) in a 20 mg/kg cohort and a 66.7% ORR in a small first-line liver-cancer combination — support the thesis but come from single-arm, small-sample studies rather than randomized proof.
Adagene's core appeal is its SAFEbody precision-masking technology, designed to keep antibodies inactive in the bloodstream and active only in the tumor, potentially enabling higher dosing with better tolerability. Validation from partners matters: the company has collaborations with Sanofi, Exelixis, Incyte, Roche, and Merck, which provide non-dilutive milestone potential and independent confirmation of the platform. A clinical collaboration with Incyte and a milestone in the Exelixis antibody-drug conjugate program illustrate this support. Positive Phase 2 data in 2027 would be the primary catalyst that could justify a re-rating toward, or beyond, the $8.50 average target.
The principal risk is clinical and binary. Adagene has no approved products and essentially no product revenue, so a disappointing Phase 2 readout could sharply reduce the shares. Even favorable data must be followed by regulatory submissions and, ultimately, commercialization — a multi-year path with financing needs. The company has already used dilutive equity offerings, including a $70 million ADS offering, and recently reported wider-than-expected losses, underscoring cash-burn pressure. Competition in immuno-oncology is intense, and historical masking approaches have produced mixed results.
On a longer-term basis, the $4.85 area marks the 52-week high and a clear resistance zone, with $3.75 — the level of a recent public offering — sitting below it as an intermediate reference. Support is evident near the roughly $2.16 low seen after an October investor event, with the 52-week low near $1.30 as the next major floor. A durable move toward $8.50 would require breaking decisively above $4.85 first.
Analyst price targets for this type of name generally reflect a roughly 12-month research horizon, though the decisive catalyst — the Phase 2 MSS CRC readout — is not expected until the first half of 2027. Investors should watch quarterly updates on that trial, additional data presentations at oncology conferences, partnership milestones, cash position and any new financing, and changes to analyst ratings or targets, which have been active recently.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. For a volatile, catalyst-driven name such as Adagene, these signals can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual screening. Explore the signals to see how AI currently reads ADAG's setup.
The $8.50 target is the average of four current analyst price targets, not a forecast of what will happen. It implies a very large — roughly 230% — move from the present price near $2.58, reflecting the wide gap between Adagene's cash-backed, pre-revenue valuation and the value analysts ascribe to a successful muzastotug outcome. The case rests on a differentiated masking platform, promising early data, and pharmaceutical partnerships; the counterweights are a binary 2027 readout, ongoing cash burn, dilution risk, and no near-term revenue. Analysts agree on direction but differ sharply on magnitude. What happens next hinges primarily on clinical data.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ADAG has been loosely correlated with CYTK. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAG jumps, then CYTK could also see price increases.
| Ticker / NAME | Correlation To ADAG | 1D Price Change % | ||
|---|---|---|---|---|
| ADAG | 100% | -0.99% | ||
| CYTK - ADAG | 34% Loosely correlated | -3.35% | ||
| SLDB - ADAG | 32% Poorly correlated | +6.63% | ||
| EDIT - ADAG | 31% Poorly correlated | +0.78% | ||
| LENZ - ADAG | 31% Poorly correlated | +16.28% | ||
| OCGN - ADAG | 31% Poorly correlated | +13.29% | ||
More | ||||